Who are Agonist GnRH; estradiol Valerate; progesterone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/agonist-gnrh-estradiol-valerate-progesterone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Agonist GnRH; estradiol Valerate; progesterone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Agonist GnRH; estradiol Valerate; progesterone (Agonist GnRH; estradiol Valerate; progesterone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone combination therapy; GnRH agonist with steroid hormones. Area: Reproductive Medicine / Fertility.

marketed Hormone combination therapy; GnRH agonist with steroid hormones GnRH receptor; estrogen receptor; progesterone receptor Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Agonist GnRH; estradiol Valerate; progesterone (Agonist GnRH; estradiol Valerate; progesterone) — Instituto Valenciano de Infertilidad, IVI VALENCIA. This combination suppresses endogenous gonadotropins via GnRH agonist while providing exogenous estradiol and progesterone to support the luteal phase during assisted reproductive cycles.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Agonist GnRH; estradiol Valerate; progesterone TARGET	Agonist GnRH; estradiol Valerate; progesterone	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	Hormone combination therapy; GnRH agonist with steroid hormones	GnRH receptor; estrogen receptor; progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone combination therapy; GnRH agonist with steroid hormones class)

Instituto Valenciano de Infertilidad, IVI VALENCIA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Agonist GnRH; estradiol Valerate; progesterone — Competitive Intelligence Brief. https://druglandscape.com/ci/agonist-gnrh-estradiol-valerate-progesterone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab